TTY Biopharm (TTY) today announced that it has formed an exclusive partnership with Everest Medicines for the commercialization of a new antibacterial drug in Taiwan. TTY has recently submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) to provide the new medical solution to both patients and doctors through the partnership that combines the competitive edges of the two companies.

Doctors have been expressing concerns that some bacteria are becoming resistant to certain available antibiotics. Even more alarming, there are an increasing number of the multiple drug resistant organisms known as“ Superbugs”in recent years. Given the fact that there are currently limited available options in Taiwan to combat these multiple drug resistant organisms, TTY and Everest Medicines, therefore, have decided to form an exclusive partnership with the aim to introduce Everest’s new antibacterial drug into Taiwan market. It is expected to grant TFDA approval at the second quarter of 2023 the earliest.

Ms. Sara Hou, CEO of TTY, said this new broad spectrum antibacterial could treat infections caused by Gram-negative and Gram-positive bacteria as well as MDRO or Superbugs infections. Indications of treatment for complicated intra-abdominal infections (cIAI) have been approved in the United States and some European countries. Some studies also show its potential to treat lung and blood infections in the future because its intestinal permeability rate is relatively higher but side effects are less comparing with traditional treatments.

Everest Medicines is a multination biopharmaceutical company focusing on developing and commercializing transformative pharmaceutical products to treat different kinds of cancers, autoimmune diseases, heart and kidney diseases and infections. It has also won a number of awards in terms of corporate innovation and precision medicine and is highly competitive in global market.
TTY hope that this partnership with Everest Medicines will continue to deepen bilateral cooperation and to generate more medical solutions to patients and doctors around the globe, she said.

“The acceptance of our New Drug Application for a new antibacterial drug and our agreement with TTY are key steps towards bringing this important and novel therapy to Taiwan,” said Kerry Blanchard, MD, PhD, Chief Executive Officer of Everest Medicines. “With a robust firm that includes expert functions in regulatory, medical, marketing and sales, and a successful record of commercializing other important anti-infective products in the region, TTY is definitely the preferred business partner as we continue our work to expand the regional reach and access of this critical therapy for patients with complicated intra-abdominal infections and other potentially life-threatening infections.”

Hou also said that the TTY has been focusing on developing a series of intensive care medicines for decades including Brosym and Lipo-AB, as well as a number of anti-infectious medicines as one of the top three pharmaceutic companies in terms of sales of Antibiotics Injection in Taiwan. Meanwhile, TTY has also been working closely with hospitals to carry out many clinical trials given the fact that collecting clinical data is crucial in terms of the development of antibacterial treatments. To further develop a cooperative and trusted partnership with the medical team.

Hou said TTY has a strong sales and marketing team that familiars with both local and international markets and has been specialized in the development, production, and the sales with liposomes and microspheres. The company also has a collaborative culture in working with its partners to pursue common goal. These characterizes showed that TTY is a trustworthy partner in the global healthcare industry.